98434-06-1 Usage
General Description
5-(2-Furyl)isoxazole-3-carboxylic acid is a chemical compound belonging to the isoxazole carboxylic acid family. It is composed of a central isoxazole ring with a furan group at the 2-position and a carboxylic acid group at the 3-position. 5-(2-FURYL)ISOXAZOLE-3-CARBOXYLIC ACID has potential applications in the field of pharmaceuticals and organic synthesis due to its unique structure and reactivity. It is also used in the preparation of various derivatives and analogs for medicinal and agrochemical purposes. The presence of the furan group and carboxylic acid functionality makes it a suitable candidate for further modification and diversification to generate new compounds with desired properties and activities.
Check Digit Verification of cas no
The CAS Registry Mumber 98434-06-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,8,4,3 and 4 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 98434-06:
(7*9)+(6*8)+(5*4)+(4*3)+(3*4)+(2*0)+(1*6)=161
161 % 10 = 1
So 98434-06-1 is a valid CAS Registry Number.
InChI:InChI=1/C8H5NO4/c10-8(11)5-4-7(13-9-5)6-2-1-3-12-6/h1-4H,(H,10,11)
98434-06-1Relevant articles and documents
ATF6 INHIBITORS AND USES THEREOF
-
Paragraph 0292; 0287; 0338; 0334; 0338; 0334; 0344; 0340, (2019/10/29)
Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.
ISOXAZOLE DERIVATIVES AND USE THEREOF
-
Page/Page column 12, (2009/05/28)
Disclosed herein are isoxazole derivatives and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/beta-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed